主权基金增持，知名医药公司大涨

Core Viewpoint - The stock of Heptagon Pharmaceuticals has surged significantly, with a year-to-date increase of approximately 700%, following a substantial investment by GIC, Singapore's sovereign wealth fund, which acquired over HKD 500 million worth of shares [1][3]. Group 1: Investment Details - GIC purchased 40.22 million shares of Heptagon Pharmaceuticals at an average price of HKD 12.7133 per share, totaling approximately HKD 5.11 billion [3]. - Following this acquisition, GIC holds a 6.37% stake in Heptagon Pharmaceuticals, making it the second-largest institutional shareholder [4]. - The largest institutional shareholder is AstraZeneca, which owns approximately 76.27 million shares, representing a 9.03% stake [4]. Group 2: Financial Performance - Heptagon Pharmaceuticals reported a total revenue of approximately RMB 725 million (around USD 101 million) for the first half of 2025, reflecting a year-on-year growth of 327% [8]. - The company's net profit for the same period reached approximately RMB 523 million (around USD 73 million), marking a staggering year-on-year increase of 51 times [8]. - Cash reserves stood at approximately RMB 2.291 billion (around USD 320 million), which is a 92% increase compared to the end of the previous year [8].